Matinas BioPharma to Present at Two Investor Conferences in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Matinas BioPharma to Present at Two Investor Conferences in Early December

- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -

- RetailInvestorConferences.com Live and Interactive Online Presentation on Thursday, December 4, 2014, at 12:00 p.m. PST / 3:00 p.m. EST -

BEDMINSTER, N.J., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting a corporate overview highlighting the recent clinical progress of Matinas BioPharma's lead product candidate MAT9001 at two upcoming investor conferences during the first week of December of 2014.

Event: LD Micro Main Event VII micro-cap investor conference
Date: Wednesday, December 3, 2014
Time: 3:00 p.m. Pacific Standard Time / 6:00 p.m. Eastern Standard Time
Location: Luxe Sunset Hotel in Los Angeles, CA

A live audio webcast of the LD Micro presentation will be available on the Company's website ( www.matinasbiopharma.com ) in the Investor Relations section under Events ( http://ir.matinasbiopharma.com/events ) with a webcast replay available approximately two hours after the presentation for a period of one month.

Event: RetailInvestorConferences.com virtual investor conference
Date: Thursday, December 4, 2014
Time: 12:00 p.m. Pacific Standard Time / 3:00 p.m. Eastern Standard Time
Location: RetailInvestorConferences.com website

A live, interactive online webcast of the RetailInvestorConferences.com presentation will be available directly through RetailInvestorConferences.com , a real-time event where investors are invited to ask questions online and may access the presenting company's "virtual trade booth." An on demand archive will be available on RetailInvestorConferences.com for 90 days. Matinas BioPharma will also post a link to the virtual conference in the Company's Investor Relations section of the corporate website under Events ( http://ir.matinasbiopharma.com/events ).

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space.  Since 2002, the firm has published reports on select companies throughout the year.  The firm also hosts the LD Micro Invitational.  LD Micro is a non-registered investment advisor.  For more information, please contact (408) 457-1042 or visit www.ldmicro.com .

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com , created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

About MAT9001

MAT9001 is a proprietary prescription-only omega-3 fatty acid-based composition, comprising docosa-pentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG > 500 mg/dL) as the lead indication. Promising pre-clinical studies with DPA and MAT9001 indicate distinctive therapeutic response properties. The Company has recently filed an IND for MAT9001 and initiated its first human study in November 2014.  The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001's differentiating mechanistic features associated with its unique composition.

About Matinas BioPharma

Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating the next generation of omega-3-fatty-acid-based pharmaceutical products. Our lead product, MAT9001, which takes advantage of advancements in the field of lipidomics, has been specifically designed and formulated for therapeutic applications in the dyslipidemia field. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter , LinkedIn , Facebook , and Google+ .

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could", "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's lead product candidate MAT9001 is in a development stage and is not available for sale or use.

Investor and Media Contact Jenene Thomas Investor Relations and Corporate Communications Advisor Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 130

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 48

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 84

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 113

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 77

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading

Top 5 Most Recently Viewed Articles

China's Investment Landscape Transformed by Market Reforms

Updated Category News Views 451

China's Market Value Reforms Enhancing Investment Confidence Recent developments in China’s market management are poised to reshape the landscape of investment, significantly boosting investor confidence. UBS analysts emphasize that these new measures represent a critical shift, aiming to cultivate a healthier environment for both domestic and foreign investors. Key...

Continue Reading
CI Financial Sees Significant Growth with Total Assets of $525B

Updated Category News Views 134

CI Financial Achieves Impressive Total Assets for October CI Financial Corp. (“CI”) (TSX: CIX) has recently announced a remarkable total asset figure of $525.3 billion. This impressive number celebrates a multifaceted asset landscape, including asset management assets totaling $136.1 billion, Canadian wealth management assets of $100.4 billion, Canadian custody assets...

Continue Reading
Carlyle Credit Income Fund Plans Second Quarter Results Update

Updated Category News Views 193

Carlyle Credit Income Fund Plans Second Quarter Results Update The Carlyle Credit Income Fund, often referred to as CCIF, has exciting news. The Fund is set to unveil its financial performance for the second quarter following market close on a specific upcoming Tuesday in May. This announcement represents a crucial moment for stakeholders and potential investors eager to...

Continue Reading
Lithia Motors Boosts Earnings: Price Target Climbs Significantly

Updated Category News Views 75

Lithia Motors Sees Price Target Hike After Strong Earnings Recently, Lithia Motors (NYSE: LAD) garnered attention in the financial markets as Stephens, a prominent financial services company, announced an increase in its price target for the automaker. The target officially rose from $360 to $405. This update follows a robust earnings report for the third quarter,...

Continue Reading
VFC Corporation Achieves 52-Week High: What it Means for Investors

Updated Category News Views 95

VFC Corporation Achieves New Market Heights In a remarkable surge, VFC Corporation's stock has reached a significant milestone by hitting a 52-week high at $20.7. This impressive figure is a clear indication of a substantial turnaround, demonstrating a remarkable 23.84% increase over the last year. Confidence among investors has rebounded as they recognize the apparel...

Continue Reading